References
1. Comeau AM, Accurso FJ, White TB, Campbell PW, Hoffman G, Parad RB,
Wilfond BS, Rosenfeld M, Sontag MK, Massie J, et al. Guidelines for
implementation of cystic fibrosis newborn screening programs: Cystic
Fibrosis Foundation workshop report. Pediatrics 2007; 119:
e495-518.
2. Wagener JS, Zemanick ET, Sontag MK. Newborn screening for cystic
fibrosis. Curr Opin Pediatr 2012; 24: 329-335.
3. Kloosterboer M, Hoffman G, Rock M, Gershan W, Laxova A, Li Z, Farrell
PM. Clarification of laboratory and clinical variables that influence
cystic fibrosis newborn screening with initial analysis of
immunoreactive trypsinogen. Pediatrics 2009; 123: e338-346.
4. Rock MJ, Mischler EH, Farrell PM, Wei LJ, Bruns WT, Hassemer DJ,
Laessig RH. Newborn screening for cystic fibrosis is complicated by
age-related decline in immunoreactive trypsinogen levels.Pediatrics 1990; 85: 1001-1007.
5. Travert G, Heeley M, Heeley A. History of Newborn Screening for
Cystic Fibrosis-The Early Years. Int J Neonatal Screen 2020; 6:
8.
6. Sontag MK, Wright D, Beebe J, Accurso FJ, Sagel SD. A new cystic
fibrosis newborn screening algorithm: IRT/IRT/DNA. J Pediatr2009; 155: 618-622.
7. Therrell BL, Hannon WH, Hoffman G, Ojodu J, Farrell PM.
Immunoreactive Trypsinogen (IRT) as a Biomarker for Cystic Fibrosis:
challenges in newborn dried blood spot screening. Mol Genet Metab2012; 106: 1-6.
8. Cystic Fibrosis Foundation Patient Registry 2020 Annual Data Report.
Bethesda, Maryland; 2020.
9. Martiniano SL, Elbert AA, Farrell PM, Ren CL, Sontag MK, Wu R,
McColley SA. Outcomes of infants born during the first 9 years of CF
newborn screening in the United States: A retrospective Cystic Fibrosis
Foundation Patient Registry cohort study. Pediatr Pulmonol 2021;
56: 3758-3767.
10. Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic fibrosis: a
worldwide analysis of CFTR mutations–correlation with incidence data
and application to screening. Hum Mutat 2002; 19: 575-606.
11. Watts KD, Layne B, Harris A, McColley SA. Hispanic Infants with
cystic fibrosis show low CFTR mutation detection rates in the Illinois
newborn screening program. J Genet Couns 2012; 21: 671-675.
12. Pique L, Graham S, Pearl M, Kharrazi M, Schrijver I. Cystic fibrosis
newborn screening programs: implications of the CFTR variant spectrum in
nonwhite patients. Genet Med 2017; 19: 36-44.
13. Sugarman EA, Rohlfs EM, Silverman LM, Allitto BA. CFTR mutation
distribution among U.S. Hispanic and African American individuals:
evaluation in cystic fibrosis patient and carrier screening populations.Genet Med 2004; 6: 392-399.
14. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick
RJ. Laboratory standards and guidelines for population-based cystic
fibrosis carrier screening. Genet Med 2001; 3: 149-154.
15. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti
M, Palomaki GE, Popovich BW, Pratt VM, Rohlfs EM, et al. Cystic fibrosis
population carrier screening: 2004 revision of American College of
Medical Genetics mutation panel. Genet Med 2004; 6: 387-391.
16. Baker MW, Atkins AE, Cordovado SK, Hendrix M, Earley MC, Farrell PM.
Improving newborn screening for cystic fibrosis using next-generation
sequencing technology: a technical feasibility study. Genet Med2016; 18: 231-238.
17. Sicko RJ, Stevens CF, Hughes EE, Leisner M, Ling H, Saavedra-Matiz
CA, Caggana M, Kay DM. Validation of a Custom Next-Generation Sequencing
Assay for Cystic Fibrosis Newborn Screening. Int J Neonatal
Screen 2021; 7: 73.
18. Martiniano SL, Croak K, Bonn G, Sontag MK, Sagel SD. Improving
outcomes for Colorado’s IRT-IRT-DNA cystic fibrosis newborn screening
algorithm by implementing floating cutoffs. Mol Genet Metab 2021;
134: 65-67.
19. McMahon R, DeMartino L, Sowizral M, Powers D, Tracy M, Caggana M,
Tavakoli NP. The Impact of Seasonal Changes on Thyroxine and
Thyroid-Stimulating Hormone in Newborns. Int J Neonatal Screen2021; 7: 8.
20. Laboratories AoPH. Overview of Cutoff Determinations and Risk
Assessment Methods used in Dried Blood Spot Newborn Screening- Role of
Cutoffs and Other Methods of Data Analysis. 2017.
https://www.aphl.org/programs/newborn_screening/Documents/
Overview%20on%20Cutoff%20Determinations%20and%20RIsk%20Assessment%20Methods_final.pdf.
[accessed 7/31/22].
21. Sosnay PR, Salinas DB, White TB, Ren CL, Farrell PM, Raraigh KS,
Girodon E, Castellani C. Applying Cystic Fibrosis Transmembrane
Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses.J Pediatr 2017; 181S: S27-S32.e21.
22. Taussig LM, Boat TF, Dayton D, Fost N, Hammond K, Holtzman N,
Johnson W, Kaback MM, Kennel J, Rosenstein BJ, et al. Neonatal Screening
for Cystic Fibrosis: Position Paper. Pediatrics 1983; 72:
741-745.
23. Padoan R, Genoni S, Moretti E, Seia M, Giunta A, Corbetta C. Genetic
and clinical features of false-negative infants in a neonatal screening
programme for cystic fibrosis. Acta Paediatr 2002; 91: 82-87.